Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the market grown over the years?

The market for tenofovir disoproxil has seen robust expansion in the last few years. The market is slated to show an increase from $3.58 billion in 2024 to $3.79 billion in 2025, boasting a compound annual growth rate (CAGR) of 5.9%. The growth during the historic period reflects the surge in awareness and early diagnosis of viral infections, a growing number of hepatitis b incidents, the widening production of generic drugs for tenofovir disoproxil, an increasing amount of clinical trials verifying tenofovir’s effectiveness, and a boost in medical funding tailored for the treatment of infectious diseases.

What Is the forecasted market size and growth rate for the market?

The market for tenofovir disoproxil is projected to witness significant expansion in the coming years, with its size set to reach $4.72 billion by 2029, growing at a compound annual growth rate (CAGR) of 5.6%. This growth during the forecast period can be attributed to factors such as increased demand for long-acting tenofovir preparations, an intensified focus on combination anti-viral therapies, increased regulatory approvals for new tenofovir combinations, priority given to pediatric tenofovir formulations, and heightened demand for tenofovir in post-exposure prophylaxis. Emerging trends to watch out for during the forecast period include the development of innovative drug delivery systems, the incorporation of artificial intelligence in drug discovery, breakthroughs in combination therapy methods, progress in nanotechnology-based delivery, and advancements in fixed-dose combination therapies.

Get your market report here!

https://www.thebusinessresearchcompany.com/report/tenofovir-disoproxil-global-market-report

What main drivers are fueling expansion in the market?

The tenofovir disoproxil market’s expansion is anticipated to be driven by the escalating occurrence of HIV and AIDS. This chronic viral infection debilitates the immune system by assaulting CD4 cells, increasing susceptibility to other infections and diseases. Unprotected sexual interactions, unawareness, limited healthcare access, and drug-resistant virus strains power the escalating incidence rate of HIV and AIDS. This is resulting in a greater demand for tenofovir disoproxil, a chief antiretroviral drug used in treatment and prevention. A report released in July 2024 by the Joint United Nations Programme on HIV/AIDS (UNAIDS), a Swiss-based government entity, revealed that by the close of 2022 around 39.5 million individuals were living with HIV globally, quoting about 1.3 million new infections for the same year. There were approximately 630,000 deaths from AIDS-related illnesses worldwide in 2022. Moreover, 39.9 million (36.1 million–44.6 million) people worldwide were living with HIV in 2023. Hence, the escalating occurrence of HIV and AIDS is propelling the tenofovir disoproxil market’s growth. An increased number of hepatitis B cases are driving demand for antiviral treatments. The tenofovir disoproxil market growth is likely to be boosted by the escalating prevalence of hepatitis B. This viral infection targets the liver, potentially leading to both acute and chronic disease, and is contracted through contact with infected blood or body fluids. Factors like perinatal transmission, hazardous medical practices, inadequate vaccination coverage, and the persistence of chronic infections in affected groups are causing a spike in hepatitis B cases. Tenofovir disoproxil is employed to treat chronic hepatitis B, as it suppresses viral replication and minimizes liver damage. As per a report released in March 2023 by the Centers for Disease Control and Prevention, a US-based public health protection agency, it is estimated that 580,000 to 2.4 million individuals in the US are living with hepatitis B infection, with about two-thirds possibly unaware of their condition. Thus, the increasing occurrence of hepatitis B is catalyzing the expansion of the tenofovir disoproxil market.

What key areas define the segmentation of the global Market?

The tenofovir disoproxil market covered in this report is segmented –

1) By Type: Tablet, Powder

2) By Distribution Channel: Online Pharmacies, Retail Pharmacies, Wholesalers Or Distributors

3) By Application: Hospital, Clinic

Subsegments:

1) By Tablet: Single-Drug Tablets, Fixed-Dose Combination Tablets

2) By Powder: Oral Powder, Reconstitutable Powder

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21296&type=smp

What are the top market players propelling the growth of the industry?

Major companies operating in the tenofovir disoproxil market are Gilead Sciences Inc., Viatris Inc., Teva Pharmaceuticals Limited, Cipla Ltd, Lupin Limited, Mylan NV, Blanver, SMS Pharmaceuticals, Bajaj Healthcare, Mangalam Drugs & Organics Ltd, Nortec Quimica, Arene Lifesciences, Cdymax, HRV Global Life Sciences, Pipelinepharma, Qilu Pharmaceutical, Jai Radhe Sales, Sinoway Industrial Co. Ltd, Aurisco Pharmaceutical, Huangshi Fuertai Pharmaceutical Tech Co. Ltd

What emerging trends are influencing the growth of the market?

Key players in the tenofovir disoproxil market are concentrating their efforts on creating novel formulations such as combination therapies to stay ahead of the competition and improve HIV/AIDS treatments. Combination therapy involves the concurrent use of two or more treatments to heighten the therapeutic impact and better the patient’s results for a specific illness. For example, Gilead Sciences Inc., an American biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) in July 2022 for Vemlidy (tenofovir alafenamide) to treat chronic hepatitis B virus (HBV) in pediatric patients aged six years and older who weigh at least 25 kg and suffer from compensated liver disease. The FDA approved Vemlidy for this younger demographic based on a Phase II clinical trial’s findings, which demonstrated the drug’s safety and effectiveness in children as young as six.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21296

What regions are dominating the market growth?

North America was the largest region in the tenofovir disoproxil market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tenofovir disoproxil market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Neuroprosthetics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neuroprosthetics-global-market-report

Neuroscience Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neuroscience-global-market-report

Diabetic Neuropathy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: